Diagnostics News - Candlesense

Science Bytes Podcast Explores How Diagnostics Can Help Protect Students and Communities

SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- With classrooms once again filled and respiratory virus season beginning, QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, i...

Symbol: QDEL

3 days ago

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensiv...

Will this new test give Labcorp a competitive edge over rivals in the neurology diagnostics market and how might it impact its market share? What is the expected adoption rate for the Lumipulse pTau‑217/Beta Amyloid 42 Ratio test versus existing Alzheimer’s diagnostics? How will the launch of the FDA‑cleared blood test affect Labcorp’s revenue forecasts and earnings guidance?

Symbol: LH

6 days ago

Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation

BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, ...

How might this development influence analyst coverage, target price revisions, and overall investor sentiment toward Bioxytran? Could the new precision diagnostics open up additional indications beyond stroke and Alzheimer’s, expanding the revenue opportunity? What are the projected costs and margins for the diagnostic platform once it reaches commercial scale?

Symbol: BIXT

9 days ago

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenat...

What are the potential risks if adoption rates of Fetal Focus™ fall short of expectations? How might this product launch influence analyst sentiment and target price revisions for NTRA? Could the launch lead to partnerships or collaborations with obstetrics and fertility clinics, and how might that affect distribution costs?

Symbol: NTRA

17 days ago